Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Zolgensma Gene Therapy Facility in Durham, North by Year
Zolgensma Gene Therapy Facility in Durham, North Carolina, US (m²)
Novartis Zolgensma Gene Therapy Facility in Durham, North: 15,794 in FY2025, unchanged from a year earlier.
Latest, FY2025
15,794
Period ended Dec 31, 2025
Change on a year earlier
0.0%
15,794 in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below
Where the FY2025 figure comes from
“|| Durham, North Carolina, US | 15 794 | Manufacture, package and release commercial Zolgensma product and certain clinical development activities”
Source: Novartis Form 20-F (0001114448-26-000004) ↗
Reported in Form 20-F Item 4.D.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Zolgensma Gene Therapy Facility in Durham, North Carolina, US (m²) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 15,794 | 0.0% | Novartis Form 20-F (0001114448-26-000004) ↗ |
| FY2024 | Dec 31, 2024 | 15,794 | 0.0% | Novartis Form 20-F (0001370368-25-000004) ↗ |
| FY2023 | Dec 31, 2023 | 15,794 | – | Novartis Form 20-F (0001370368-24-000004) ↗ |
Cite this data
StockData. (2026). Novartis Zolgensma Gene Therapy Facility in Durham, North, annual FY2023–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/fac-durham-m2
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.